XBiotech (XBIT) Total Debt (2024)

XBiotech (XBIT) posted Total Debt of $10.0 million for Q4 2024, little changed on a QoQ basis from $10.0 million in Q3 2024.

Analysis

XBiotech (XBIT) Total Debt (2024) Analysis & Trends

XBiotech has reported Total Debt for 1 years, with the latest figure at $10.0 million in Q4 2024.

On a quarterly basis, Total Debt changed N/A year-over-year to $10.0 million in Q4 2024; TTM through Dec 2024 was $10.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $10.0 million, changed N/A from the prior year.
Total Debt was $10.0 million for Q4 2024 at XBiotech, roughly flat from $10.0 million in the prior quarter.
The five-year high for Total Debt was $10.0 million in Q1 2024, with the low at $10.0 million in Q1 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn	62.75 Bn
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn	28.66 Bn
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn	1.99 Bn
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn	-
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn	591.00 Mn
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn	-
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn	8.09 Bn
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn	-
10	XBiotech	66.16 Mn	66.16 Mn	-	-

Historic Data

Download Data